Search results
Showing 76 to 90 of 410 results for infection control
Tegaderm CHG securement dressing for vascular access sites in critically ill adults (HTG379)
Evidence-based recommendations on Tegaderm CHG securement dressing for vascular access sites in critically ill adults.
Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.
VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (HTG362)
Evidence-based recommendations on VibraTip for testing vibration perception to detect diabetic peripheral neuropathy.
Evidence-based recommendations on interferon alfa (Pegasys or ViraferonPeg) and ribavirin for people with chronic hepatitis C.
Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)
Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.
Read the biographies for all members of the NICE antimicrobial evaluation committee.
This guideline covers identifying and caring for adults who are malnourished or at risk of malnutrition in hospital or in their own home or a care home. It offers advice on how oral, enteral tube feeding and parenteral nutrition support should be started, administered and stopped. It aims to support healthcare professionals identify malnourished people and help them to choose the most appropriate form of support.
Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)
Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults.
This quality standard covers the management of acute upper gastrointestinal bleeding in adults and young people (aged 16 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS38Show all sections
Sections for QS38
- Quality statements
- Quality statement 1: Risk assessment
- Quality statement 2: Immediate endoscopy for people who are haemodynamically unstable
- Quality statement 3: Endoscopy within 24 hours for people who are haemodynamically stable
- Quality statement 4: Endoscopic treatment for non-variceal bleeding
- Quality statement 5: Treatment of non-variceal bleeding after first or failed endoscopic treatment
- Quality statement 6: Prophylactic antibiotic therapy for variceal bleeding
- Quality statement 7: Band ligation for oesophageal variceal bleeding
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)
Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis in adults
The MIST Therapy system for the promotion of wound healing (HTG267)
Evidence-based recommendations on the MIST Therapy system for the promotion of wound healing.
Deep brain stimulation for refractory chronic pain syndromes (excluding headache) (IPG382)
Evidence-based recommendations on deep brain stimulation for refractory chronic pain syndromes (excluding headache). This involves stimulating a precise area of the brain using an electrode to treat the chronic pain.
View recommendations for IPG382Show all sections
Sections for IPG382
The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)
NICE has developed a medtech innovation briefing (MIB) on the OraQuick HCV point-of-care test for rapid detection of hepatitis C virus antibodies
XprESS multi sinus dilation system for treating chronic sinusitis (HTG424)
Evidence-based recommendations on the XprESS multi-sinus dilation system for treating chronic sinusitis after medical treatment has failed.
NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .